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ORIGINAL ARTICLE
Predicting patients at risk for pain associated with 
electrochemotherapy
PIETRO QUaGLINO1, LOUIsE WICHmaNN maTTHIEssEN2, PIETRO CURaTOLO3, 
TOBIaN mUIR4, GIULIa BERTINO5, CHRIsTIaN KUNTE6, JOY ODILI7, 
ROBERTa ROTUNNO3, aLIsON CLaIRE HUmPHREYs8, VaLERIE LETULé6, 
FEDERICa maRENCO1, CaROL CUTHBERT7, RIKKE aLBRET9, maRCO BENazzO5, 
FRaNCEsCa DE TERLIzzI10 & JULIE GEHL2
1Department of Medical Sciences, Dermatologic Clinic, University of Torino, Torino, Italy, 2Center for Experimental 
Drug and Gene Electrotransfer, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark, 
3Department of Dermatology and Plastic Surgery, Dermatologic Clinic, University of Rome “La Sapienza”,  
Rome, Italy, 4Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, UK, 
5Department of Otolaryngology Head & Neck Surgery, University of Pavia, IRCCS Policlinico, San Matteo 
Foundation, Pavia, Italy, 6Department of Dermatology and Allergology, Ludwig-Maximilian University Munich, 
Munich, Germany, 7Department of Plastic Surgery, St. Georges Hospital, London, UK, 8Department of Oncology, 
James Cook University Hospital, Middlesbrough, UK, 9Department of Anaesthesiology, University of Copenhagen, 
Herlev Hospital, Herlev, Denmark and 10IGEA S.p.a., Via Parmenide, 10/A Carpi, Italy
AbstrAct
background. Electrochemotherapy describes the use of electric pulses to enhance chemotherapy uptake, and has proven 
highly efficient in treating cutaneous metastases. Patients referred for electrochemotherapy present with diverse clinical 
pictures, from multiple small lesions to large, ulcerated lesions. Post-electrochemotherapy pain has been observed in 
some patients. The objectives of this study were to evaluate pain scores before and after electrochemotherapy, and to 
investigate if patients at risk of post-procedure pain could be identified.
Methods. Seven cancer centres in the International Network for Sharing Practices on Electrochemotherapy (INSPECT) 
consecutively and prospectively reported to a common database. Electrochemotherapy consisted of intratumoural or 
intravenous injection of bleomycin, followed by delivery of electric pulses in local or general anesthesia.
results. Of 121 patients 39% had metastatic melanoma, 18% squamous cell carcinoma, 16% breast cancer, 13% basal-
cell carcinoma, and 14% other malignancies. Median size of the largest nodules was 2.3 cm (range 0.3–40 cm). A 
majority of patients presented with low pain scores, and this continued through follow-up (74%). A subset of patients 
had moderate (13%) or severe pain (13%) after treatment. Post-procedure pain was statistically significantly associated 
with: 1) moderate or severe pain before treatment (p  0.0001); 2) size of the largest treated lesion (p  0.01); 3) previ-
ous irradiation (p  0.02); and 4) high treatment current value (p  0.0001).
conclusion. The majority of patients had no or mild pain after electrochemotherapy. Patients at risk for post-procedure 
pain could be identified at the pre-treatment visit, and/or at the time of treatment, enabling a pain management strategy 
for this group.
Electrochemotherapy is a new but already well estab-
lished local treatment modality for disseminated cuta-
neous metastases of different malignancies including 
melanoma, squamous-cell and basal-cell carcinoma, 
breast cancer and Kaposi sarcoma [1–17]. a recent 
meta-analysis showed an overall response rate for 
electrochemotherapy of cutaneous metastases at 
75%, with a complete response rate of 47% [18].This 
promising technique combines the antitumour activ-
ity of non-permeant (e.g. bleomycin) anticancer drugs 
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with short intense electrical pulses [19,20]. Electric 
pulses are delivered locally and increase cell perme-
ability enhancing drug uptake into tumour cells, thus 
increasing the intracellular concentration and toxic-
ity of the administered agent. Consistently, impres-
sive clinical activity has been reported, with high 
complete response rates in treated cutaneous metas-
tases. Besides the clinical activity in terms of response 
rates, electrochemotherapy has been shown to exert 
a palliative role in reducing discomfort and pain from 
cutaneous metastases [9,12].
Patients referred for electrochemotherapy present 
with diverse disease manifestations; from the mela-
noma patient with multiple small cutaneous metas-
tases, to the patient with cutaneous recurrence of 
breast cancer up to 40 cm, as evidenced in this study. 
In earlier studies, where smaller cutaneous metasta-
ses were treated, pain has not been reported as a 
significant issue [4,9,10]. However, as the technology 
has been applied to patients with larger cutaneous 
metastases, pain has been reported as a more 
frequent side effect [12].
The International Network on sharing Practices 
for Electrochemotherapy (INsPECT) database was 
formed to be able to answer questions of importance 
for use of electrochemotherapy. The objectives of this 
study were to evaluate pain scores before and after 
electrochemotherapy, and to investigate if a subset of 
patients at risk of pain could be identified.
Patients
Patients were treated consecutively at seven institu-
tions in the INsPECT network (Rome, middles-
brough, Turin, Pavia, munich, London, Copenhagen). 
Centres included patient data prospectively to the 
same database. approval from ethics committee, and 
data protection authority was according to each insti-
tution. Clinical information retrieved by the database 
included: demographics; type of tumour; number of 
treated lesions, site and size of the largest lesion, pre-
vious irradiation (it was registered whether a cutane-
ous metastasis was in a previously irradiated field, 
but not what dose or fractionation had been given), 
duration of follow-up, possible retreatment with elec-
trochemotherapy at subsequent time point.
Patients treated had histologically proven cancer 
with measurable cutaneous metastases, or mucosal 
lesions, suitable for application of electric pulses, or 
had primary non-melanoma skin cancer, where other 
options were exhausted or not possible. Patients had 
been offered standard treatment options, were  18 
years old, had ECOG performance status  2, a life 
expectancy of at least three months, and if fertile were 
using adequate contraception. Patients were not treated 
if they previously had allergic reactions to bleomycin 
or to any of the components required for anaesthesia, 
if the cumulative dose of 250 mg bleomycin/m2 
(400.000 IU bleomycin/m2) had previously been 
exceeded, had chronic renal dysfunction (serum crea-
tinine  150 mmol/l) or acute lung infection.
Methods
Procedure
Electrochemotherapy was performed based on the 
standard operating procedures published in 2006 
[12,21]. Briefly, bleomycin (manufacturer according 
to practice of the institution) was administrated either 
intratumourally (i.t.) using 1000 IU/ml or intrave-
nously (i.v.) using 15.000 IU/m2, intratumoural or 
intravenous dosage was chosen depending on the 
number of cutaneous metastases to be treated and size 
of metastases. Likewise, local anesthesia was used for 
small or few metastases, whereas general anaesthesia 
was preferred for multiple metastases, large metasta-
ses ( 3 cm), metastases adhering to the periosteum 
or situated in sensitive regions (e.g. face and scalp), 
and in accordance with patient preference. Depending 
on clinician’s choice, one of the following electrodes 
was used: 1) Type I electrodes: two plates with a 6 mm 
gap between the plates; 2) Type II electrodes: two par-
allel rows of needles with 4 mm between rows; 3) Type 
III electrodes: a hexagonal array with 7.9 mm between 
the needles. Electric pulses (eight pulses of 100 ms 
duration) were delivered using a square wave elec-
troporator (IGEa, Carpi, Italy). The applied voltage 
relative to distance between electrodes was 1.3 kV/cm 
for plate electrodes and 1.0 kV/cm for needle elec-
trodes, i.e. for the type II needle electrode with a 4 
mm gap the applied voltage was 400 V. For type I and 
II electrodes, the pulses are applied with 1 Hz or 5 
kHz, whereas for type III electrodes, pulses can only 
be applied with 5 kHz. after electrochemotherapy, the 
treated metastases were covered with standard dress-
ings where necessary.
Response evaluation
Tumour response was evaluated according to the 
Response Evaluation Criteria in solid Tumours 
(RECIsT version 1.0), modified to only include 
response of the treated cutaneous metastases. a max-
imum of seven cutaneous metastases per patient 
(including the largest tumour) were registered as 
target lesions, as in previous studies [4,10].
Pain assessment
Pain assessment was performed at four time points: 
before treatment, within 24 hours after treatment, 
thereafter within 45 days from treatment and after 
D
ow
nl
oa
de
d 
by
 [M
ax
ill
o F
ac
cia
li]
 at
 05
:44
 14
 Se
pte
mb
er 
20
15
 
300 P. Quaglino et al. 
more than 45 days from treatment. Pain intensity was 
evaluated using the Numeric Rating scale (NRs) for 
pain [22]. NRs is a uni-dimensional 11-point 
numeric scale in which the patient is asked to indi-
cate a whole number (between “0” as “no pain” and 
“10” as “worst pain”) in a horizontal bar. Respon-
dents were asked to indicate their average pain inten-
sity related to cutaneous metastases. We used a 
previously published cut-off on NRs score [23]: 0–2 
mild pain, 3–4 moderate pain, 5–10 severe pain. Pain 
medication was registered as ‘none’, ‘sometimes’, 
‘controlled by non-opioids’, ‘controlled by opioids’, 
‘uncontrolled’, or ‘unknown’.
Statistics
sPss (statistical Packages for social sciences) 15.0 
was used. Continuous variables were expressed as 
mean, median, standard deviation and range, cate-
gorical variables as frequencies and percentages. 
Comparisons between couples of groups were per-
formed with two-tailed heteroschedastic student’s 
t-test for continuous variables, and c2-test with Yate’s 
continuity correction. Comparison among the three 
pain groups were performed with aNOVa test (con-
tinuous variables) and c2-test (categorical variables). 
Generalised linear model was applied for indepen-
dent predictors of pain within 45 days after treatment: 
categorical variables were tested using a reference 
group (group “other diagnosis” versus: “metastatic 
melanoma”, “breast cancer”, “squamous cell carci-
noma”, “basal cell carcinoma”; group “abdomen, 
back, genitalia” versus: “upper/lower limbs”, “head/
neck, scalp, intraoral”, “chest”; group “previous irra-
diation” versus “no previous irradiation”).
Results
Patients
a total of 124 patients were included, three were lost 
to follow-up due to: progressive disease (two patients) 
and death not related to procedure (one patient). a 
total of 121 patients with cutaneous metastases were 
included in this analysis from seven centres belonging 
to the INsPECT network: Rome (n  28), middles-
brough (n  23), Turin (n  19), Pavia (n  18), 
munich (n  14), London (n  11), Copenhagen 
(n  8). accrual time was from July 2007 to may 
2012. The main demographics and clinical character-
istics of these patients are summarised in Table I. 
Figure 1 shows representative images of the various 
clinical presentations. The pain evaluation was avail-
able for all 121 patients before and at one or more 
points after electrochemotherapy. Figure 2 shows per-
centage of patients for whom pain data was available 
at the respective time points, and Table II lists pain 
medication at the respective time points. Twenty-one 
patients received a subsequent treatment with elec-
trochemotherapy; the median time between two ses-
sions was 63 days (range 16 days–5.6 months).
Reported pain scores before and after treatment
Pain assessment was performed using standard NRs 
score before treatment, within 24 hours after treat-
ment, within 45 days from treatment and after more 
than 45 days from treatment.
a majority of patients did not experience pain 
before treatment (60% with NRs score  0), this 
Table I. Patient demography and treatment choices.
Pre-treatment visit (121 patients) No %
Gender
– male
– female
53
68
44%
56%
age (years)
– median
– range
72
39–95
Diagnosis
– metastasis of malignant melanoma
– squamous cell carcinoma
– Breast cancer
– Basal cell carcinoma
– Kaposi sarcoma
– sarcoma
– adenocarcinoma (not breast)
– merkel cell carcinoma
– othersa
47
22
19
16
6
5
3
1
2
39%
18%
16%
13%
5%
4%
2%
1%
2%
site of the largest nodule
– Head and neck
– scalp
– intraoral
– chest
– abdomen
– back
– genitalia
– upper limbs
– lower limbs
36
1
3
32
6
4
3
5
31
30%
1%
3%
26%
5%
3%
2%
4%
26%
Number of treated nodules (per patient)b
– median
– range
2
1–7
size of the largest nodule (cm)
– median
– range
2.3
0.3–40
Bleomycin admninistration
– Local
– systemic
17
104
14%
86%
anaesthesia
– Local
– General
49
72
40%
60%
Electrodes used
– Plate
– Row needle
– Hexagonal
Combination
7
35
69
10
6%
29%
57%
8%
 aendometrial cancer, metastatic metatypical cell carcinoma; bonly 
up to 7 nodules registered per patient.
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percentage dropped to 43% within 24 hours after 
treatment, and rose again to 57% and 66%, respec-
tively, within 45 days and after 45 days from treat-
ment (Figure 2). Patients presenting with larger 
tumours had higher pain scores before treatment 
(mean NRs in patients with largest metastasis over 
3 cm was 2.3  2.6, and for patients with smaller 
metastases 1.3  2.2, p  0.02).
Of the patients experiencing pain, the majority 
had scores from 1 to 3 (Figure 2).
Trends in NRs scores during treatment were 
coupled with the analysis of pain medications taken 
by the patients (Table II). The percentage of patients 
not taking pain medication increased after treatment, 
and it is noteworthy that only a small percentage of 
patients took opioids at baseline (9.1%); and this 
percentage fell after treatment (Table II). Overall, 
patients needed less pain medication after treatment 
(p  0.0069).
Correlation of pain scores with other factors
a series of parameters potentially associated with the 
severity of pain within 45 days after treatment have 
been analysed. The results are shown in Table III. 
age, gender, type of tumour, site of cutaneous 
metastases were not associated with increased pain 
severity. size of metastases and previous irradiation 
were associated with a significant increase in pain 
severity after electrochemotherapy (p  0.008 and 
p  0.014, respectively). For parameters related to 
treatment, higher current value (more than 5 a) was 
significantly associated to pain (p  0.0001). a 
strong predictor of pain at follow-up was actually 
pain before treatment, and also within 24 hours after 
treatment (p  0.0001).
multivariate analysis was also performed, and here 
pain before and after treatment were considered as 
numerical ordinal variables, as well as electric current 
intensity. The results of the model showed that signifi-
cant independent predictors of high pain intensity 
within 45 days after electrochemotherapy are: pre- 
treatment high pain intensity (B  0.521  0.088, 
p  0.0001), high current intensity (B  0.476  0.157, 
p  0.002), diagnosis of melanoma (B  1.236  0.567, 
p  0.029) and breast cancer (B  2.312  0.890, 
p  0.009) compared to other diagnoses (where B is the 
coefficient in the model).
Tumour response
Response data are listed in Table IV. statistical anal-
ysis showed significant correlation between reported 
pain and tumour response (p  0.0029).
Discussion
Electrochemotherapy is a new therapeutic procedure 
which is increasingly being used to treat cutaneous 
metastases from different tumours. Initially only smaller 
cutaneous tumours were reported to be treated [1,24], 
but development of the technology and publication of 
standard operating procedures [21] as well as further 
clinical studies [9,25] have led to treatment also of 
considerably larger cutaneous metastases [12].
as evidenced in the demography of the present 
patient population, metastases vary from very small 
(3 mm) to very large cutaneous metastases (400 mm), 
are of different histology and with various previous 
Figure 1. Clinical characteristics of patients. Patients referred for 
electrochemotherapy present with quite different clinical problems. 
Top panels: 93-year-old male patient with squamous cell carcinoma 
of the scalp before treatment (left) and after three treatments 
(right), treated at University of Rome. middle panels: 88-year-old 
female patient with multiple metastases of malignant melanoma 
on left lower leg, recurrence after several other treatments including 
surgery and radiotherapy (left side). Four months after one session 
with electrochemotherapy (right side) all cutaneous and 
subcutaneous metastases regressed. Typical hyperpigmentation 
and fibrosis of the skin. Lower panels; 58-year-old female patient 
with extensive relapse and metastases of breast cancer of the chest 
wall, accompanied by extensive bleeding and malodour (left side). 
Eight weeks after first electrochemotherapy session, regression of 
exophytic tumors, cessation of bleeding and malodur. Development 
of new metastases at the border of the treated area. Latter two 
cases treated in Ludwig-maximilian Institute, munich.
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treatments. Figure 1 gives an impression of the diver-
sity of clinical presentations.
Numerous studies have demonstrated the high 
clinical activity of electrochemotherapy in terms of 
both response rate and duration [1–16]. However, one 
of the issues which became evident, in particular when 
treating larger tumours, was that even though electro-
chemotherapy may reduce pain from cutaneous 
metastases [9], the procedure itself may also induce 
this symptom as a subset of patients can develop post-
treatment pain [12]. Pain is treatable, and the under-
standing of the distribution, time of onset and 
duration, as well as the identification of patients 
more likely to experience pain after electrochemo-
therapy, allows rational therapeutic strategies for 
pain control.
Figure 2. Percentage distribution of patients in relation to their pain score. The reported pain relating to treated cutaneous metastases 
using numeric rating scale (NRs) is illustrated in (a) before treatment, (B) within 24 hours from treatment – either after completion of 
treatment in local anaesthesia or before discharge from hospital in the case of general anaesthesia, (C) within 45 days from treatment, (D) 
after more than 45 days from treatment.
Table II. Distribution of patients with regards to pain medication before electrochemotherapy, at follow-up within 45 days after treatment, 
and at follow-up after more than 45 days from treatment.
Before 
electrochemotherapy
at follow-up within 45 
days from treatment
at follow-up after more than 45 
days from treatment
Pain medication N % N % N %
None 44 36.4 45 46.4 52 56.5
sometimes, controlled by non-opioids 40 33.0 31 32.0 17 18.5
Controlled by non-opioids 20 16.5 10 10.3 15 16.3
Controlled by opioids 11 9.1 6 6.2 2 2.2
Uncontrolled 3 2.5 4 4.1 5 5.4
Unknown 3 2.5 1 1.0 1 1.1
Total 121 100.0 97 100 92 100
D
ow
nl
oa
de
d 
by
 [M
ax
ill
o F
ac
cia
li]
 at
 05
:44
 14
 Se
pte
mb
er 
20
15
 
 Predicting patients at risk for pain after electrochemotherapy  303
the procedure, and rose again to 57% and 66%, 
respectively, within 45 days after treatment and after 
more than 45 days from treatment (Figure 2).
Thirty percent of patients reported NRs scores 
of 3 or higher before electrochemotherapy, indicating 
that some patients may have a need for intervention 
at first consultation. Interestingly, the data very 
This study shows, that the majority of patients 
referred for electrochemotherapy come with low pain 
scores, and continue to have low pain scores after 
treatment (Figures 2, 3 and Table II–IV). Thus, of the 
121 patients a majority of patients did not experience 
pain before treatment (60% with NRs score  0), this 
percentage dropped to 43% at within 24 hours after 
Table III. Pain intensity at follow-up within 45 days: association with parameters recorded at pre-treatment visit, and treatment data.
NRs BY GROUPs 0–2 3–4 5–10 statistics
TOTaL (95 patients) 71 12 12
No % No % No % p-Value
Gender
– male
– female
33
38
46%
54%
4
8
33%
67%
4
8
33%
67%
c2 n.s.
(p  0.532)
age (years)
– median
– range
– mean  st.dev.
74
41–94
71.0  12.9
80
42–88
75.6  13.0
74
46–94
71.6  16.0
aNOVa
n.s.
(p  0.544)
Diagnosis
– metastasis of malignant melanoma
– squamous cell carcinoma
– Breast cancer
– Basal cell carcinoma
– Others*
22
14
10
11
14
31%
20%
15%
16%
18%
8
3
1
0
0
67%
25%
8%
0%
0%
5
2
3
1
1
42%
17%
25%
8%
8%
c2 n.s.
(p  0.249)
site of the largest nodule
– Head and neck (scalp, intraoral)
– Trunk (chest, abdomen, back, genitalia)
– Limbs (upper limbs, lower limbs)
28
24
19
39%
35%
26%
3
3
6
25%
25%
50%
5
2
5
42%
17%
41%
c2 n.s.
(p  0.414)
size of the largest nodule (cm):
– median
– range
– mean  st.dev.
2.0
0.3–20
3.8  4.3
5.3
0.4–12
5.7  4.9
3.7
0.7–40
9.7  12.7
aNOVa
p  0.0080
Current value
– 0–1.5 a
– 1.5–3 a
– 3–5 a
–  5 a
9
31
12
8
15%
52%
20%
13%
3
0
5
4
25%
0%
42%
33%
0
1
2
9
0%
8%
17%
75%
c2
p  0.0001
Previous irradiation
– yes
– no
8
52
13%
87%
3
9
25%
75%
6
6
50%
50%
c2
p  0.014
NRs pre-treatment
– median (range)
– mean  st.dev.
0 (0–8)
0.9  1.6
4 (0–9)
3.8  3.0
5 (0–8)
4.7  2.6
aNOVa
p  0.0001
NRs post-treatment
– median (range)
– mean  st.dev.
1 (0–9)
1.4  1.9
4 (0–8)
4.4  2.1
2 (0–8)
2.8  3.0
aNOVa
p  0.0001
 *others: 6 Kaposi sarcoma, 5 sarcoma, 2 adenocarcinoma (non-breast), 1 merkel cell carcinoma, 1 other.
Table IV. Pain intensity at follow-up: relationship with the response per patient on the largest nodule.
NRs BY GROUPs 0–2 3–4 5–10 statistics
TOTaL (95 pts) 71 12 12
No % No % No % p-Value
CR
PR
sD
PD
Na
38
20
10
2
1
54%
28%
14%
3%
1%
1
6
4
0
1
8%
50%
34%
0%
8%
5
2
2
3
0
41%
17%
17%
25%
0%
c2
p  0.0045
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304 P. Quaglino et al. 
clearly shows, that a high pain score before treatment 
is highly significantly correlated with pain scores 
after treatment; thus a very obvious recommendation 
would be to assess patients for pain at the first visit 
and institute an immediate, as well as a post-treat-
ment and follow-up pain management plan.
Furthermore, the data analysis shows that previ-
ous irradiation to the treatment area is associated 
with increased risk for post-electrochemotherapy 
pain. Late post-surgical pain may also be a contribu-
tor, in particular for the breast cancer patients, and 
indeed diagnosis of breast cancer was an indepen-
dently significant variable predicting pain.
a high current value was statistically correlated 
to pain within 24 hours from treatment (p  0.0001). 
High current values during treatment are seen when 
tissue is highly conductive (typically the ulcerated, 
necrotic cutaneous metastases), and/or when a larger 
part of the needle electrode is immersed in tumour 
tissue (i.e. exophytic or deep metastases). From this 
study we would not be able to answer whether the 
current by itself has an effect on pain after electro-
chemotherapy, or whether high current levels are 
only reflective of large and/or ulcerated metastases, 
which could be painful. However, large current val-
ues seen at the procedure may give an indication of 
expected post-treatment pain levels. Thus, in the 
group of 12 patients with severe pain on follow-up, 
75% were treated with current levels of over 5 a, 
whereas the picture was very different for the other 
groups.
size of the treated cutaneous metastases (largest 
diameter of largest lesion) was also significantly cor-
related with post-treatment pain, and this again may 
reflect a metastasis which is larger, possibly necrotic, 
and with longer healing time.
multivariate analysis was performed, and con-
firmed NRs pre-treatment and high current value 
during treatment as predictors of post-procedure 
pain. also diagnoses of breast cancer and malignant 
Figure 3. Change in numeric rating scale score for pain before and after treatment. The change in numeric rating scale (NRs) score for 
pain with respect to NRs score before treatment is illustrated for (a) within 24 hours from treatment – either after completion of treatment 
in local anaesthesia or before discharge from hospital in the case of general anaesthesia, (B) within 45 days from treatment, (C) after more 
than 45 days from treatment. 0  no change,  1  one score up from baseline value (e.g. from NRs  3 to NRs  4), and likewise -1  one 
score down.
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melanoma came out as positive predictors. However, 
the number of patients in the analysis is small for a 
multivariate analysis, so these results should be inter-
preted with some caution.
In another study [13] increasing incidence of 
pain was found with repetitive treatments. Thus, 
increased attention should also be paid to this patient 
group, where progression or widespread/large cuta-
neous metastases necessitates several treatments. 
This finding would be in line with the conclusions 
of this study that previous treatment with radiation 
increases risk of pain, i.e. that the number of inter-
ventions has an impact.
In a previous publication from the INsPECT 
database on a cohort of 52 patients with cutaneous 
metastases from different tumours, pain develop-
ment was reported in the area treated by electro-
chemotherapy 1–2 days after treatment in only five 
patients (10%) [10]. studies on melanoma patients 
reported no significant pain after electrochemother-
apy [7], or that post-treatment pain was common but 
manageable with minor analgesics [14]. Other stud-
ies observed, however, that in breast cancer patients, 
pain was one of the major morbidities of the treat-
ment and increased after re-treatments, reported as 
“moderate to severe” by 6%, 13% and 17% of 
patients after the first, second, and third application, 
respectively [13]. similarly, in another study on 
breast cancer patients, severe pain occurred in seven 
patients (44%) and in four of them, was resistant to 
increased dosage of opioids and lasted up to two 
months, with neuropathic features [12].
In this study, an important overall finding was 
that overall pain values were reduced after electro-
chemotherapy, and pain medication significantly 
reduced.
In conclusion, this study clearly indicates, that a 
group of patients at risk for pain after electrochemo-
therapy may be identified, and that these patients are 
actually identifiable at the pre-treatment visit. 
although institutional guidelines and practice may 
vary, this guideline may serve to identify patients at 
risk of pain, and to plan accordingly for the patient.
What may also be learnt from this study is that 
post-treatment pain is not a main concern for most 
patients receiving electrochemotherapy, and that also 
this group will be identifiable by the lack of the above 
mentioned risk factors. Finally, our data show that 
pain levels and pain medication overall decrease after 
electrochemotherapy. 
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